Comparative Pharmacology
Head-to-head clinical analysis: IODOTOPE versus MPI INDIUM DTPA IN 111.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IODOTOPE versus MPI INDIUM DTPA IN 111.
IODOTOPE vs MPI INDIUM DTPA IN 111
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodine-131 is taken up by the thyroid gland and emits beta particles and gamma rays, causing destruction of thyroid tissue via radiation-induced cell death.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
For thyroid ablation: 3.7-5.55 MBq (100-150 μCi) orally as a single dose. For hyperthyroidism: 185-555 MBq (5-15 mCi) orally as a single dose.
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
None Documented
None Documented
Terminal half-life is approximately 120-140 days for total body iodine, but the effective half-life for therapeutic use is 8-13 days due to biological turnover in the thyroid. For diagnostic use, effective half-life is 1-2 days.
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
Primarily renal: >90% excreted in urine as iodide. Fecal excretion is negligible (<2%).
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical